Opioid Use Disorder

Current data support naltrexone use as medication for opioid use disorder in pregnancy, with encouraging perinatal outcomes, according to a systematic review published in Obstetrics & Gynecology.

Patients with opioid use disorder, or OUD, who were treated with buprenorphine during an ED visit had greater odds of continued treatment engagement 30 days later, a study in JAMA Network Open showed.

Children who were exposed to opioids prenatally faced greater risks for infection, eczema and dermatitis, and asthma, but not for allergies, anaphylaxis or autoimmune diseases, according to a study published in JAMA Network Open.

Substance use-related CVD deaths increased at an average of 4% per year from 1999 to 2019, with alcohol and opioids the most common contributors, despite an overall reduction in CVD mortality in the U.S. during the same period, data show.

Residential addiction treatment centers serving adolescents are scarce and expensive in the United States, new study findings suggest, despite increasing overdose rates among young people in recent years.

Some of the most-viewed stories on Healio Psychiatry over the past year highlighted the FDA designating an at-home depression treatment as a breakthrough device as well as the transformative power of psychedelics.

Below is a list of stories involving substance use and children that were published by Healio in 2023.

The FDA has approved AvertD, the first DNA test to identify an elevated risk for developing opioid use disorder, according to a press release.

Screening for opioid use disorder, or OUD, in primary care clinics did not increase the percentage of new OUD diagnoses, according to results from a cluster randomized trial published in the Annals of Internal Medicine.

Opioid overdoses are the number one cause of accidental death in the United States, and rates of mental health diagnoses are rising exponentially.